Breakthrough First of Kind Technologies Will Be Presented
LOS ANGELES, March 20, 2013 /PRNewswire/ — Heart Failure 2013 LA will be held at the Millennium Biltmore Hotel all day on Saturday April 6th. Leonhardt Ventures and the Cal-X Stars Life Science Business Accelerator are co-sponsoring @ 5:30pm a side showcase of startups that address heart and cardiovascular disease, most of them based in Southern California or with strong SoCal ties.
Companies to be showcased include:
MyoStim Pacers – http:/www.myostimpacers.com – world's first heart failure pacemaker with ability to recruit repairative stem cells to damaged and weakened heart tissue.
Bioheart, Inc. – http://www.bioheartinc.com – Phase III leader in applying adult muscle stem cells to treat advanced heart failure. Only cell type known to grow new contractile muscle in the depths of scar tissue.
BioPace – world's first biological pacemaker made entirely of living cells.
CoroStim – world's first vibrational energy emitting pacemaker that prevents plaque formation in high risk coronary arteries.
BioLeonhardt – – combination electrical stimulation and multi-stage cell and gene therapy method, composition and devices for treating advanced heart failure. Featuring combined utilization of MicroRNAs, nutrient time release SDF-1, hydrogel, cardiac stem cells, iPS cells and muscle progenitor stem cells. First method under testing with up to 36 repeat injection sessions of stem cells over time via a needle catheter.
Cardiobridge – http://www.cardiobridge.com – Highest flow rate 10FR circulatory support catheter pump in clinical testing for acute decompensating heart failure and high-risk PCI. Data on about 30 clinical patients will be presented.
AortaCell – Method and device to treat aortic aneurysms non-invasively with an abdominal belt that delivers focal wireless electrical energy to weakened aortic wall that causes repairative autologous stem cells to home to that chosen treatment location.
EndoCell – Method and device for growing new endothelium lining of a damaged artery with a percutaneous needle catheter and endothelial progenitor cells.
MyoValve – Cell seeding method and device for heart valve leaflets invivo or invitro. Designed to reduce risk of calcification and valve replacement.
Valvublator – Percutaneous catheter device for de-calcifying heart valves so a patient may keep their own valve instead of getting an artificial implant.
HeartScore – Composite scoring system of genetic, blood and scan test results (some point of care) that are loaded into the SecondBeat wearable wrist watch for a baseline score. The watch has an infrared sensor that measures real time endothelial health. The baseline score goes up or down if the patient eats well, exercises well and is compliance with all doctor prescribed medicines and protocols. The composite HeartScore is clearly viewable to patients to help real time guidance of their heart and cardiovascular health.
About Leonhardt Ventures: Since 1983 Leonhardt Ventures www.leonhardtventures.com has a strong history of inventing, developing, backing and bringing to market leadership products for treating heart and cardiovascular disease. Over 200,000 patients have been treated to date with Leonhardt inventions. In the 1980's the group developed market leadership in patented polyurethane balloon catheters including drug, stem cell and radiation delivery systems. In the 1990s they developed over 20 additional devices including the first commercially successful stent graft for aortic aneurysm repair (TALENT – Taheri-Leonhardt Stent Graft). The team completed the first ever truly percutaneous repair of an aortic aneurysm without surgery in Melbourne, Australia in 1995. Published the first thoracic aortic dissection repair with stent grafts paper in The New England Journal of Medicine in 1999. The first conformance sealing stent graft. The first above renal fixation stent graft. The first customized to fit individual patient stent grafts. The first multi-stage low profile stent graft. The first removable stent graft. The first foam and bioglue sealing cuff for stent grafts. The first use of muscle stem cells to reinforce aortic wall necks after stent graft placement. The team developed and patented the first percutaneous heart valve, intravascular lung catheter, the Pro-Cell intracavity stem cell delivery system and the MyoCath line of stem cell delivery catheters. Leonhardt patented inventions include the first heart pacemaker able to recruit repairative stem cells to damaged heart tissue (MyoStim Pacers). In 2001 the team led the first in the world non-surgical case of stem cell repair of damaged heart muscle in a human patient with Bioheart MyoCell. That led to the first Phase III double blinded, randomized, placebo controlled trial for stem cells growing new contractile muscle in post heart attack tissue in advanced heart failure patients – results published in the American Heart Journal Bioheart MyoCell pts 95.7 meters improvement in exercise capacity over placebo (minus 4 meters decline). The team is preparing to complete the first ever biological pacemaker implantation in a human patient within the next 12 months (BioPace).
About Cal-X Stars: Cal-X Stars is a 5 year program business accelerator based in Santa Monica, California. Cal-X Stars also operates Cal-Xelerator a 12 week business startup launch accelerator. Both Cal-X Stars and Cal-Xelerator specialize in life science companies with a stem cell focus and social good enterprises with positive cash flow. Both accelerators guide firms through the California Qualification By Permit financings up to $5 million via Cal-X Crowdfund Connect www.calxcrowdfund.com
About Heart Failure 2013 LA: Is officially endorsed by the Heart Failure Society of America. Heart Failure 2013 http://www.laheartfailure.com has been designed to continue a tradition of providing a comprehensive, high level and clinically oriented update on prevention, diagnosis and management of heart failure. The program is structured to include lectures presented by experts in the field combined with interactive panel discussions. In addition the program will provide an update on cutting edge therapies including the use of gene therapy, neuroregulin and stem cell therapy in patients with heart failure.
Contact: Howard Leonhardt, Leonhardt Ventures, 1531 6th Street, Unit 401, Santa Monica, California, 90401, 310 310 2534, Email